{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=42", "query": { "condition": "Refractory B-cell Non-Hodgkin Lymphoma", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 1227, "total_pages": 123, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-cell+Non-Hodgkin+Lymphoma&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-18T15:41:51.801Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05588440", "title": "A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed/Refractory Aggressive B-Cell Malignancies" ], "interventions": [ { "name": "ONCT-808", "type": "BIOLOGICAL" }, { "name": "Bridging Therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Oncternal Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-05-09", "completion_date": "2024-09-12", "has_results": true, "last_update_posted_date": "2024-12-05", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 4, "location_summary": "Duarte, California • Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05588440" }, { "nct_id": "NCT00085150", "title": "LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "LMB-2 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 40, "start_date": "2004-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Portland", "state": "Oregon" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085150" }, { "nct_id": "NCT02950220", "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3a Follicular Lymphoma", "Mediastinal Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Kami Maddocks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-01-12", "completion_date": "2019-01-03", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02950220" }, { "nct_id": "NCT04673617", "title": "AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "AB-101", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-03-29", "completion_date": "2025-10-06", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Orange, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04673617" }, { "nct_id": "NCT00104923", "title": "Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "fenretinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "California Cancer Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 29, "start_date": "2005-02", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2017-07-19", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 4, "location_summary": "Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00104923" }, { "nct_id": "NCT02978235", "title": "A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "NonHodgkin Lymphoma" ], "interventions": [ { "name": "TAS4464", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-03-01", "completion_date": "2018-02-01", "has_results": false, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 7, "location_summary": "Bethesda, Maryland • Boston, Massachusetts • Farmington Hills, Michigan + 4 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978235" }, { "nct_id": "NCT06014762", "title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (tFL)", "Follicular Lymphoma Grade 3B", "DLBCL", "DLBCL - Diffuse Large B Cell Lymphoma", "DLBCL Arising From Follicular Lymphoma", "DLBCL, Diffused Large B Cell Lymphoma", "DLBCL NOS" ], "interventions": [ { "name": "P-CD19CD20-ALLO1", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-04-16", "completion_date": "2041-03", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 16, "location_summary": "Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06014762" }, { "nct_id": "NCT00009776", "title": "Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "monoclonal antibody Lym-1", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "indium In 111 monoclonal antibody Lym-1", "type": "RADIATION" }, { "name": "yttrium Y 90 monoclonal antibody Lym-1", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00009776" }, { "nct_id": "NCT01799889", "title": "Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Diffuse Large B-cell Lymphoma", "Non-FL Indolent Non-Hodgkin's Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "Entospletinib MM", "type": "DRUG" }, { "name": "Entospletinib SDD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 326, "start_date": "2013-03-14", "completion_date": "2020-01-30", "has_results": true, "last_update_posted_date": "2020-11-19", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01799889" }, { "nct_id": "NCT00003913", "title": "Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 390, "start_date": "1998-12", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-10-18T15:41:51.801Z", "location_count": 23, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003913" } ] }